Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 630 participants.

Also called NCT07144956

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 630 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07144956
  • EU CT 2024-516468-27-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07144956. Randomized; triple masking; primary purpose treatment. Start 2025-12-15 (anticipated); primary completion 2029-12-14 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage
Acronym
CASH
Condition
Aneurysmal Subarachnoid Hemorrhage
Intervention (Biological)
Cilostazol (Pletal®) 100 mg Tablets
Intervention (Drug)
Placebo
Intervention (Drug)
Nimodipine group
Lead sponsor
Centre Hospitalier St Anne (class: other)

Record details

Record id
cardio:ct-nct07144956
Content hash
acee1a100e13be774aa08f4053a2b639240037ca2713238fe0249f93d254ec0b